Great overview.

I was ISN member before, I want to remain part of ISN, like active member.
what I need to do to make my payments and current status.

Thanks for the great work. Tinzaparin is one LMWH that I had not have to use, but would strongly consider it.
I wished if you have touched on VKA use in ESRD patients.

excelent review. very interesting

excellent literature review of use of low molecular weight heparin and unfractionated heparin. I am more aware now about the use of tinzaparin and I am looking forward to the results of TRIVET study. Enoxaprin is frequently used at our institution for ESRD patient population at reduced dosages, however, there is clearly not enough data on the regimen to be used in such patients. Risk of life threatening bleeading (intracranial bleeding) needs to be weighed against the risk of deadly PE's. These are very difficult decisions to make for both patients and clinicians.

Very nice lecture! There might be one more point you might wish to comment, and it really trouble us in every day practice regarding ESRD patients under dialysis. Increased risk of calciphylaxis due to VKA use. What alternatives do we have? for example when treating a patient under dialysis who also suffers from AF. Thanks again for the presentation!